ABSTRACT
Background Obstetric risk factors are among the leading preventable causes of Acute Kidney Injury (AKI) in hospitalized reproductive age women. Obstetric-related AKI (ORAKI) has been linked to a significant increase in the overall burden of AKI in resource-constrained settings, resulting in poor maternal and perinatal outcomes. As a result, understanding the impact of these factors on the progression of AKI is critical for a positive outcome. The study sought to determine the incidence of CKD and death, and the effect of obstetric risk factors on these outcomes among reproductive age women with dialysis requiring AKI at the national renal transplant center in Ethiopia.
Methods A retrospective cohort study was conducted on 127 AKI cases (57 ORAKI and 70 None-ORAKI) who were on dialysis at the center from January 2018 to June 2020. A posthoc power analysis was calculated using G*Power 3.19.4. Data characterization and comparison was made using frequencies with percentages, median with interquartile range, chi-square test/ Fischer’s exact test and Mann-Whitney U test. A Robust Poisson regression model was used to identify factors that influence the progression of AKI to CKD and death, with Adjusted Relative Risk (ARR), 95% CIs for ARR, and P-values reported for result interpretation.
Results The overall incidence rate (IR) of CKD was 5.4 per 1000 Person-days (PD) (ORAKI group=0 and None-ORAKI group= 9.7 per 1000 PD) and the overall incidence rate of death was 7.8 per 1000 PD (ORAKI group=5.5 per 1000 PD and None-ORAKI group= 9.7 per 1000 PD). According to the multivariable regression analysis, participants with ORAKI had a 22% lower risk of progression to CKD or death than those with None-ORAKI (ARR=0.78, 95%CI=0.67-0.90, p=0.001).
Conclusions Although having obstetric related risk factors has been linked to an increased risk of developing AKI, once it occurs, those with ORAKI have a significantly better prognosis than those with None-ORAKI. Continued efforts to prevent AKI in pregnant women and to slow its progression once it has developed are critical for a better maternal and fetal outcome.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted after securing ethical clearance from St. Paul's Hospital Millennium Medical College institutional review board (SPHMMC-IRB). The St. Paul's Hospital Millennium Medical College institutional review board (SPHMMC-IRB) also waived the need for informed consent since the study used secondary data (IRB letter no: PM.23/724). The study was carried out in accordance with relevant guidelines and regulations. Medical record number was used for the data collection and personal identifiers of the patient were not used in the research report. Access to the collected information was limited to the research team and confidentiality was maintained throughout the project.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
List of Abbreviations
- ACEIs/ARBs
- Angiotensin-Converting Enzyme Inhibitors/ Angiotensin II Receptor Antagonists
- AKI
- Acute kidney injury
- ATN
- Acute Tubular Necrosis
- AGN
- Acute Glomerulonephritis
- CI
- Confidence interval
- Cr
- Creatinine
- HELLP
- hemolysis, elevated liver enzymes, and low platelets
- HIV
- Human immunodeficiency virus
- IRB
- Institutional review board
- ICU
- Intensive Care Unit
- NSAIDs
- Non-steroidal anti-inflammatory drugs
- ORAKI
- Obstetric Related Acute Kidney Injury
- RR
- Relative Risk
- PIGN
- Post-infectious Glomerulonephritis
- PPI
- Proton Pump Inhibitors
- RPGN
- Rapidly Progressive Glomerulonephritis